Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
暂无分享,去创建一个
S. Heller | R. Pratley | J. Eriksson | C. Desouza | T. Sathyapalan | Ofri Mosenzon | S. Rosenlund | T. M. Blicher | O. Hels